Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NP-101 in Solid Tumors
NCT06563375Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2025
- Primary completion
- Sep 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of pritumumab in solid tumor (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Safety and Adverse Events at 1 year. Started Mar 2025; status: recruiting.
02
Drugs
pritumumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06563375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06563375.